Physician profile
Robert William Cherry
NPI 1144851148
$3,636.16
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,203 · 2022: $702 · 2023: $791 · 2024: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,731.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $665.41 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $388.04 | 2021-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $311.19 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $283.52 | 2021-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $227.33 | 2021-2024 | Caplyta |
| Corium, LLC | $221.99 | 2022-2024 | Azstarys |
| Bausch Health US, LLC | $206.90 | 2021-2022 | |
| Alkermes, INC. | $170.51 | 2021-2024 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $164.16 | 2021-2024 | Austedo Xr |
| Axsome Therapeutics, INC. | $155.65 | 2023-2024 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $127.69 | 2021-2023 | Hetlioz, Fanapt |
| Sunovion Pharmaceuticals INC. | $122.25 | 2021-2022 | |
| Lundbeck LLC | $104.22 | 2022-2024 | Rexulti |
| Tris Pharma INC | $90.98 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $61.80 | 2023-2024 | Ingrezza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $58.95 | 2021-2024 | Loreev Xr |
| Adlon Therapeutics L.P. | $48.19 | 2021 | |
| Janssen Pharmaceuticals, INC | $46.10 | 2023-2024 | Spravato |
| Jazz Pharmaceuticals INC. | $44.23 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $40.20 | 2022-2024 | Quviviq |
| Harmony Biosciences LLC | $35.61 | 2023-2024 | Wakix |
| Ironshore Pharmaceuticals INC. | $33.30 | 2023-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $15.36 | 2024 | |
| Allergan, INC. | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.